Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm (COR-ART)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ChanRx Corporation
ClinicalTrials.gov Identifier:
NCT01691313
First received: September 20, 2012
Last updated: October 29, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)